Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2026 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...
July 30, 2026 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon to Report Q2 2026 Financial Results on August 6, 2026

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...
July 30, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight

New York, USA, July 30, 2026 (GLOBE NEWSWIRE) -- Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape |...
July 29, 2026 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 29, 2026 07:05 ET | Source: Anika Therapeutics Inc.

Anika Reports Second Quarter 2026 Financial Results

Commercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020 Raising Full-Year...
July 29, 2026 07:00 ET | Source: BIOXYTRAN, INC.

Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research

Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran’s A-SUQAR commercial distribution agreement ...
July 28, 2026 16:01 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
July 28, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight

New York, USA, July 28, 2026 (GLOBE NEWSWIRE) -- Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight The...
July 28, 2026 08:30 ET | Source: Bicara Therapeutics Inc.

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...
July 28, 2026 08:00 ET | Source: Standard BioTools Inc.

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation...